MDRNA, Inc. Gets Full Control Over its Gene Technology from RiboTask ApS
Reuters -- MDRNA Inc. said it gained full financial and transactional control over the use of its technology for the development of RNAi, or gene silencing-based, therapeutics from RiboTask ApS.